Cerubidine, Vyxeos liposomal (previously known as vyxeos)(daunorubicin)
Cerubidine, Daunorubicin, Daunoxome, Vyxeos (daunorubicin) is a small molecule pharmaceutical. Daunorubicin was first approved as Cerubidine on 1982-01-01. It is used to treat myeloid leukemia acute and precursor cell lymphoblastic leukemia-lymphoma in the USA. It has been approved in Europe to treat myeloid leukemia acute.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Cerubidine, Daunorubicin (discontinued: Cerubidine, Daunorubicin, Daunoxome)
CombinationsVyxeos
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Daunorubicin citrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DAUNOXOME | Galen Pharma | N-050704 DISCN | 1996-04-08 | 1 products |
Hide discontinued
Cytarabine
+
Daunorubicin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VYXEOS | Jazz Pharmaceuticals | N-209401 RX | 2017-08-03 | 1 products, RLD, RS |
Daunorubicin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DAUNORUBICIN HYDROCHLORIDE | Hikma Pharmaceuticals | N-050731 RX | 1998-01-30 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| daunorubicin hydrochloride | ANDA | 2025-05-21 |
| vyxeos | New Drug Application | 2025-07-01 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CYTARABINE / DAUNORUBICIN, VYXEOS, CELATOR PHARMS | |||
| 2028-03-30 | ODE-350 | ||
| 2024-08-03 | ODE-287 | ||
| 2024-03-30 | NPP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Cytarabine / Daunorubicin, Vyxeos, Celator Pharms | |||
| 10028912 | 2032-10-15 | DP | U-3149, U-3150 |
| 10166184 | 2032-10-15 | DP | U-3149 |
| 10835492 | 2032-10-15 | U-3150 | |
| 8092828 | 2029-04-01 | U-3147 | |
| 8022279 | 2027-09-14 | DP | U-3147 |
| 7850990 | 2027-01-23 | DP | U-3147 |
| 9271931 | 2027-01-23 | DP | |
| 8518437 | 2026-06-07 | DP | |
| 8431806 | 2025-04-22 | DP | U-3147 |
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01D: Cytotoxic antibiotics and related substances
— L01DB: Anthracyclines and related substances
— L01DB02: Daunorubicin
— L01X: Other antineoplastic agents in atc
— L01XY: Combinations of antineoplastic agents
— L01XY01: Cytarabine and daunorubicin
Clinical
Clinical Trials
2485 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 66 | 298 | 164 | 11 | 38 | 536 |
| Lymphoma | D008223 | — | C85.9 | 90 | 279 | 120 | 10 | 17 | 460 |
| Leukemia | D007938 | — | C95 | 105 | 214 | 116 | 24 | 21 | 424 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 130 | 187 | 90 | 8 | 24 | 377 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 34 | 102 | 62 | 21 | 16 | 218 |
| Myeloid leukemia | D007951 | — | C92 | 66 | 102 | 42 | 5 | 11 | 187 |
| Sarcoma | D012509 | — | — | 49 | 91 | 44 | 1 | 13 | 180 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 36 | 88 | 43 | 3 | 6 | 154 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 45 | 94 | 34 | 2 | 4 | 152 |
| Lymphoid leukemia | D007945 | — | C91 | 19 | 58 | 32 | 15 | 6 | 120 |
Show 34 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 60 | 43 | 14 | — | 5 | 109 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 18 | 27 | 15 | — | 1 | 55 |
| Recurrence | D012008 | — | — | 23 | 20 | 7 | — | 2 | 47 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 8 | 21 | 15 | — | 2 | 46 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 8 | 26 | 11 | — | 5 | 45 |
| Monocytic leukemia acute | D007948 | — | — | 10 | 18 | 11 | — | 1 | 36 |
| Myelomonocytic leukemia acute | D015479 | — | C92.5 | 10 | 18 | 10 | — | 1 | 36 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 11 | 19 | 6 | — | 3 | 35 |
| Erythroblastic leukemia acute | D004915 | EFO_1001257 | C94.0 | 8 | 15 | 10 | — | 1 | 31 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 11 | 16 | 7 | — | — | 30 |
Show 137 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Blast crisis | D001752 | — | — | 3 | 9 | — | — | — | 12 |
| Plasmablastic lymphoma | D000069293 | — | C83.3 | 7 | 7 | — | — | — | 11 |
| Invasive hydatidiform mole | D002820 | — | D39.2 | — | 8 | — | — | — | 8 |
| Adult t-cell leukemia-lymphoma | D015459 | — | C91.5 | 4 | 4 | — | — | — | 7 |
| Aids-related lymphoma | D016483 | EFO_1001365 | — | 3 | 4 | — | — | — | 7 |
| Myeloid leukemia chronic-phase | D015466 | — | — | 3 | 3 | — | — | — | 6 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 2 | 6 | — | — | — | 6 |
| Head and neck neoplasms | D006258 | — | — | 4 | 5 | — | — | — | 6 |
| Intestinal neoplasms | D007414 | — | C26.0 | 2 | 4 | — | — | — | 6 |
| Primary effusion lymphoma | D054685 | — | C83.8 | 4 | 4 | — | — | — | 5 |
Show 116 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Appendiceal neoplasms | D001063 | EFO_0003880 | C18.1 | 2 | — | — | — | 1 | 3 |
| Cystadenocarcinoma | D003536 | — | — | 2 | — | — | — | — | 2 |
| Neoplasms by histologic type | D009370 | — | — | 2 | — | — | — | — | 2 |
| Sezary syndrome | D012751 | — | C84.1 | 1 | — | — | — | 1 | 2 |
| Female genital neoplasms | D005833 | — | — | 2 | — | — | — | — | 2 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Leukemia myeloid chronic atypical bcr-abl negative | D054438 | — | C92.2 | 1 | — | — | — | — | 1 |
| Thrombocytosis | D013922 | — | D75.83 | 1 | — | — | — | — | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | — | — | — | — | 1 |
| Cutaneous malignant melanoma | D000096142 | — | — | 1 | — | — | — | — | 1 |
Show 10 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 2 | 2 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | — | — | 2 | 2 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | — | — | — | 2 | 2 |
| Biliary tract neoplasms | D001661 | — | C24.9 | — | — | — | — | 1 | 1 |
| Fatigue | D005221 | — | R53.83 | — | — | — | — | 1 | 1 |
| Ataxia | D001259 | — | R27.0 | — | — | — | — | 1 | 1 |
| Ataxia telangiectasia | D001260 | Orphanet_100 | G11.3 | — | — | — | — | 1 | 1 |
| Telangiectasis | D013684 | — | — | — | — | — | — | 1 | 1 |
| Cerebellar ataxia | D002524 | — | — | — | — | — | — | 1 | 1 |
| Alopecia areata | D000506 | EFO_0004192 | L63 | — | — | — | — | 1 | 1 |
Show 22 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Daunorubicin |
| INN | daunorubicin |
| Description | Daunorubicin is a natural product found in Actinomadura roseola. It has a role as an antineoplastic agent and a bacterial metabolite. It is an anthracycline, a member of tetracenequinones, a member of p-quinones and an aminoglycoside antibiotic. It is a conjugate base of a daunorubicin(1+). It derives from a hydride of a tetracene. |
| Classification | Small molecule |
| Drug class | antineoplastic antibiotics (daunorubicin type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 |
Identifiers
| PDB | — |
| CAS-ID | 20830-81-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL178 |
| ChEBI ID | 41977 |
| PubChem CID | 30323 |
| DrugBank | DB00694 |
| UNII ID | ZS7284E0ZP (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Vyxeos – Jazz Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 23,705 documents
View more details
Safety
Black-box Warning
Black-box warning for: Daunorubicin hydrochloride, Vyxeos
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
16,199 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use